Skip to main content

Main menu

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
American Society of Nephrology
  • Other
    • ASN Publications
    • JASN
    • Kidney360
    • Kidney News Online
    • American Society of Nephrology
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Advertisement
American Society of Nephrology

Advanced Search

  • Home
  • Content
    • Published Ahead of Print
    • Current Issue
    • Podcasts
    • Subject Collections
    • Archives
    • Kidney Week Abstracts
    • Saved Searches
  • Authors
    • Submit a Manuscript
    • Author Resources
  • Trainees
    • Peer Review Program
    • Prize Competition
  • About CJASN
    • About CJASN
    • Editorial Team
    • CJASN Impact
    • CJASN Recognitions
  • More
    • Alerts
    • Advertising
    • Feedback
    • Reprint Information
    • Subscriptions
  • ASN Kidney News
  • Visit ASN on Facebook
  • Follow CJASN on Twitter
  • CJASN RSS
  • Community Forum
Editorials
You have accessRestricted Access

Keeping Up with the Times

Prognostic Tools in ANCA-Associated Glomerulonephritis

Silke R. Brix and Duvuru Geetha
CJASN August 2020, 15 (8) 1078-1080; DOI: https://doi.org/10.2215/CJN.09600620
Silke R. Brix
1Division of Cardiovascular Science, University of Manchester, Manchester, United Kingdom
2Renal, Transplantation and Urology Unit, Manchester Royal Infirmary, Manchester University Hospitals National Health Service Foundation Trust, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Silke R. Brix
Duvuru Geetha
3Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • View PDF
Loading
  • ANCA
  • vasculitis
  • glomerulonephritis
  • outcomes

The ANCA-associated vasculitides are characterized by systemic necrotizing vasculitis involving small vessels and accompanied by the presence of circulating ANCAs. Left untreated, they are fatal, and therapeutic advances in the last 2 decades have transformed them to a disease of relapsing and remitting course with associated morbidity. Nowadays, mortality from active disease is exceeded by mortality due to therapy-related adverse events during the first year (1). Identification of clinical and histologic factors predictive of treatment response, relapse risk, and kidney and patient survival remains an unmet need in the management of ANCA-associated vasculitides. Identification of these predictors would assist in personalization of therapy.

Kidney involvement is common, occurring in over 80% of patients during the disease course, and it portends higher mortality rate. Despite advances in therapy, kidney failure occurs in 20%–30% of patients and negatively influences patient survival. Identifying patients at risk for kidney failure is imperative to balance the risk of progression to dialysis against the risk of adverse events from immunotherapy. The prognostication of kidney disease continues to pose a significant clinical challenge given the lack of validated clinical and pathologic correlates, but the kidney biopsy has diagnostic and prognostic value in ANCA-associated vasculitis.

Considering the prognostic value of the kidney biopsy, an international working group of kidney pathologists proposed a classification in 2010 on the basis of the changes in glomerular pathology. ANCA-associated GN was categorized into four classes addressing the extent and age of glomerular lesions: the focal, crescentic, mixed, and sclerotic classes (2). The validation study, performed in a cohort of 100 patients enrolled in European vasculitis trials, demonstrated that this classification predicted 1- and 5-year kidney survival. The focal class had the best kidney prognosis, followed by the crescentic, mixed, and sclerotic classes. Subsequent validation studies in other cohorts showed differential outcome in one of the four classes, with most inconsistency between the crescentic and mixed classes. Multivariable analyses adjusting for kidney function, percentage of normal glomeruli, or tubular atrophy and interstitial fibrosis demonstrated that using the four classes did not improve outcome prediction (3,4). A meta-analysis of 17 studies encompassing 1540 adult patients found no difference in kidney survival between crescentic and mixed class GN (5). Moreover, up to 50% of patients in the sclerotic class respond to immunotherapy and recover kidney function.

Bajema and colleagues recommended using the percentage of normal glomeruli to predict kidney function in ANCA-associated GN already in 1999 when investigating a multicenter cohort. Forming the European Vasculitis Society (EUVAS) working group, the investigators reviewed biopsies of the methyl-prednisolone versus plasma exchange trial for severe kidney vasculitis and stated that normal glomeruli were the predictor of dialysis independence and improvement in kidney function, indicating that the unaffected part of the kidney is vital in determining kidney outcome (6). The ANCA classification working group decided then to use a cutoff for glomerular lesions of 50% (2). Hillhorst detected in 2013 that patients’ kidney survival of the crescentic and mixed classes, which initially had not differed, was indeed different when applying a cutoff for normal glomeruli of 25%. In a multicenter, prospective cohort of over 100 patients, a regression tree detected two cutoffs for normal glomeruli predicting kidney survival: at 23.3% and 5% (7). Similar to the clinical picture of advanced kidney disease, where very little kidney function seems often enough to keep patients dialysis independent, a significantly smaller amount of normal glomeruli than 50% seems to decide kidney survival in ANCA-associated GN.

The severity of kidney dysfunction at diagnosis has been associated with reduced kidney survival. Validation in large interventional cohorts demonstrated that an eGFR<15 ml/min independently affected kidney survival (1). Nonetheless, in a retrospective study of 155 patients with severe ANCA-associated GN, >14% of patients with an average eGFR at entry of <10 ml/min and highest chronicity score responded to immunosuppressive therapy (8). The combination of baseline kidney function and histologic parameters has been shown to be a better predictor of kidney outcome than baseline kidney function alone. Different glomerular lesions have extensively been investigated for their prediction value. In a beautiful investigation, the EUVAS working pathologists reviewed biopsies in great detail in 2002. Here, Hauer and colleagues showed that the amount of normal glomeruli correlated with kidney function at diagnosis, achieving a mediocre strength of correlation (r=0.53). Other glomerular parameters, however, failed to demonstrate more than weak Pearson correlation coefficients to kidney function at diagnosis and after 18 months of follow-up. The kidney function at diagnosis was the single predictor of kidney function after 18 months of sufficient strength (r=0.67). The reversibility of different glomerular injuries is controversial. The point of no return when a glomerulus fails to cope with a glomerular injury is unknown. In a more recent prospective cohort, different glomerular damage scores were tested (7). The percentage of normal glomeruli and, inversely, the score counting all glomerular lesions were the most accurate predictors of kidney survival, superior to scores omitting or reducing the effect of fibrinoid necrosis and segmental lesions.

A novel tool called the ANCA kidney risk score was developed and validated by Brix et al. (7). This clinicopathologic score includes three parameters: baseline eGFR, percentage of normal glomeruli, and degree of tubular atrophy and interstitial fibrosis on the kidney biopsy. A prospective cohort was investigated for clinical and histopathologic glomerular and interstitial lesions. A tree analysis detected cutoffs for normal glomeruli, tubular atrophy and interstitial fibrosis, and kidney function separating patient cohorts as per development of kidney failure, and no arbitrary cutoffs were set. According to Cox regression, risk factors were assigned points, and a risk score was calculated ranging from zero to 11 points. This risk score was used to define three differing risk groups for kidney failure: low (zero points), medium (two to seven points), and high (more than eight points). The risk model was then validated and confirmed in an independent patient cohort.

There are histopathologic scoring and classification systems in clinical use for IgA and diabetic nephropathy. Ten years on from the initial proposal of the classification for ANCA-associated GN and many validation studies later, the classification has not been adjusted yet. In this CJASN issue, the original investigators validated classification and score in a further cohort and performed a meta-analysis of 21 publications. van Daalen et al. (9) analyzed a retrospective multicenter cohort of 145 patients diagnosed over a period of 20 years (1991–2011). During a mean follow-up of 8 years, only 17% of patients developed kidney failure. The smallest biopsy included in the study contained five glomeruli. Interobserver variability accounted for a 68% agreement of allocating biopsies into the four classes. Results of the new cohort as well as the meta-analysis confirmed the previous findings that the focal class has the best outcome, the sclerotic class has the worst outcome, and the crescentic and mixed classes show similar kidney survival.

Investigating the aspect of improvement in kidney function in this validation cohort, the crescentic class demonstrated a temporary improvement in ΔeGFR at 1 year follow-up, but the mixed class did not. This difference was not detectable in the ΔeGFR at 5 years of follow-up. The authors stated that they feared the clinical and histopathologic differences would be lost if the crescentic and mixed classes were merged now. Therefore, they decided to re-evaluate the classification addressing tubulointerstitial changes and reinvestigating glomerular lesions.

Validating the ANCA score, the authors confirmed the distinction between the risk groups, with significantly differing outcomes of the low-, medium-, and high-risk groups (0%, 10%, and 31%, respectively). Rates of kidney failure were lower compared with the German cohort, which comparatively had a lower baseline eGFR. Since its publication in 2018, the score has been investigated in first-validation cohorts. A recent cohort from Turkey demonstrated similar findings to the initial German cohort investigated by Brix et al. (7). The rates of kidney failure were 8%, 42%, and 67% in the low-, medium-, and high-risk groups, respectively, over a median follow-up of 39 months (10). A further cohort from Mexico enriched with mixed and sclerotic class GN, a group at high risk of progression to kidney failure, confirmed the risk groups’ distinction. Kidney survival rates were 100%, 85%, and 37% according to the low-, medium-, and high-risk groups, respectively, after 36 months follow-up (11).

ANCA-associated vasculitides present in very different clinical scenarios. A risk stratification assisting in management of these vulnerable patients will help to personalize medicine. Applying clinicopathologic risk stratification will represent a major advance in the management of ANCA-associated GN. Investigating large, prospective cohorts of interventional trials will enable us to improve our prognostic tools; adjust cutoffs; and include additional prognostic clinical parameters such as age, ANCA subtype, and type of induction therapy. Scoring systems and classifications using parameters that predict outcome will adapt over time to achieve our goal to provide patients with a realistic prognosis and tailor their therapy accordingly.

Disclosures

D. Geetha reports receiving consultant fees from Aurinia and ChemoCentryx outside the submitted work. The remaining author has nothing to disclose.

Funding

None.

Acknowledgments

The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or CJASN. Responsibility for the information and views expressed herein lies entirely with the author(s).

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

  • See related article, “Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis,” on pages 1103–1111.

  • Copyright © 2020 by the American Society of Nephrology

References

  1. ↵
    1. Flossmann O,
    2. Berden A,
    3. de Groot K,
    4. Hagen C,
    5. Harper L,
    6. Heijl C,
    7. Höglund P,
    8. Jayne D,
    9. Luqmani R,
    10. Mahr A,
    11. Mukhtyar C,
    12. Pusey C,
    13. Rasmussen N,
    14. Stegeman C,
    15. Walsh M,
    16. Westman K
    ; European Vasculitis Study Group: Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70: 488–494, 2011pmid:21109517
    OpenUrlCrossRefPubMed
  2. ↵
    1. Berden AE,
    2. Ferrario F,
    3. Hagen EC,
    4. Jayne DR,
    5. Jennette JC,
    6. Joh K,
    7. Neumann I,
    8. Noël LH,
    9. Pusey CD,
    10. Waldherr R,
    11. Bruijn JA,
    12. Bajema IM
    : Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 21: 1628–1636, 2010pmid:20616173
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Moroni G,
    2. Binda V,
    3. Leoni A,
    4. Raffiotta F,
    5. Quaglini S,
    6. Banfi G,
    7. Messa P
    : Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature. Clin Exp Rheumatol 33[Suppl 89]: S-56–S-63, 2015pmid:26016751
    OpenUrlPubMed
  4. ↵
    1. Tanna A,
    2. Guarino L,
    3. Tam FW,
    4. Rodriquez-Cubillo B,
    5. Levy JB,
    6. Cairns TD,
    7. Griffith M,
    8. Tarzi RM,
    9. Caplin B,
    10. Salama AD,
    11. Cook T,
    12. Pusey CD
    : Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: Evaluation of the international histological classification and other prognostic factors. Nephrol Dial Transplant 30: 1185–1192, 2015pmid:25016608
    OpenUrlCrossRefPubMed
  5. ↵
    1. Chen YX,
    2. Xu J,
    3. Pan XX,
    4. Shen PY,
    5. Li X,
    6. Ren H,
    7. Chen XN,
    8. Ni LY,
    9. Zhang W,
    10. Chen N
    : Histopathological classification and renal outcome in patients with antineutrophil cytoplasmic antibodies-associated renal vasculitis: A study of 186 patients and metaanalysis. J Rheumatol 44: 304–313, 2017pmid:27980013
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. de Lind van Wijngaarden RA,
    2. Hauer HA,
    3. Wolterbeek R,
    4. Jayne DR,
    5. Gaskin G,
    6. Rasmussen N,
    7. Noël LH,
    8. Ferrario F,
    9. Waldherr R,
    10. Hagen EC,
    11. Bruijn JA,
    12. Bajema IM
    : Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 17: 2264–2274, 2006pmid:16825335
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Brix SR,
    2. Noriega M,
    3. Tennstedt P,
    4. Vettorazzi E,
    5. Busch M,
    6. Nitschke M,
    7. Jabs WJ,
    8. Özcan F,
    9. Wendt R,
    10. Hausberg M,
    11. Sellin L,
    12. Panzer U,
    13. Huber TB,
    14. Waldherr R,
    15. Hopfer H,
    16. Stahl RAK,
    17. Wiech T
    : Development and validation of a renal risk score in ANCA-associated glomerulonephritis. Kidney Int 94: 1177–1188, 2018pmid:30385041
    OpenUrlCrossRefPubMed
  8. ↵
    1. Lee T,
    2. Gasim A,
    3. Derebail VK,
    4. Chung Y,
    5. McGregor JG,
    6. Lionaki S,
    7. Poulton CJ,
    8. Hogan SL,
    9. Jennette JC,
    10. Falk RJ,
    11. Nachman PH
    : Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. Clin J Am Soc Nephrol 9: 905–913, 2014pmid:24578329
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. van Daalen EE,
    2. Wester Trejo MAC,
    3. Göçeroğlu A,
    4. Ferrario F,
    5. Joh K,
    6. Noël L-H,
    7. Ogawa Y,
    8. Wilhelmus S,
    9. Ball MJ,
    10. Honsova E,
    11. Hruskova Z,
    12. Kain R,
    13. Kimura T,
    14. Kollar M,
    15. Kronbichler A,
    16. Lindhard K,
    17. Puéchal X,
    18. Salvatore S,
    19. Szpirt W,
    20. Takizawa H,
    21. Tesar V,
    22. Berden AE,
    23. Dekkers OM,
    24. Hagen EC,
    25. Oosting J,
    26. Rahmattulla C,
    27. Wolterbeek R,
    28. Bos WJ,
    29. Bruijn JA,
    30. Bajema IM
    : Developments in the histopathological classification of ANCA-associated glomerulonephritis. Clin J Am Soc Nephrol 15: 1103–1111, 2020
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Gercik O,
    2. Bilgin E,
    3. Solmaz D,
    4. Cakalagaoglu F,
    5. Saglam A,
    6. Aybi O,
    7. Kardas RC,
    8. Soypacaci Z,
    9. Kabadayi G,
    10. Yildirim T,
    11. Kurut Aysin I,
    12. Karadag O,
    13. Akar S
    : Histopathological subgrouping versus renal risk score for the prediction of end-stage renal disease in ANCA-associated vasculitis. Ann Rheum Dis 79: 675–676, 2020pmid:32041747
    OpenUrlFREE Full Text
  11. ↵
    1. Mejía-Vilet JM,
    2. Martín-Nares E,
    3. Cano-Verduzco MSL,
    4. Pérez-Arias AA,
    5. Sedano-Montoya MA,
    6. Hinojosa-Azaola A
    : Validation of a renal risk score in a cohort of ANCA-associated vasculitis patients with severe kidney damage. Clin Rheumatol 39: 1935–1943, 2020pmid:31970548
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Clinical Journal of the American Society of Nephrology: 15 (8)
Clinical Journal of the American Society of Nephrology
Vol. 15, Issue 8
August 07, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
View Selected Citations (0)
Print
Download PDF
Sign up for Alerts
Email Article
Thank you for your help in sharing the high-quality science in CJASN.
Enter multiple addresses on separate lines or separate them with commas.
Keeping Up with the Times
(Your Name) has sent you a message from American Society of Nephrology
(Your Name) thought you would like to see the American Society of Nephrology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Keeping Up with the Times
Silke R. Brix, Duvuru Geetha
CJASN Aug 2020, 15 (8) 1078-1080; DOI: 10.2215/CJN.09600620

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
Keeping Up with the Times
Silke R. Brix, Duvuru Geetha
CJASN Aug 2020, 15 (8) 1078-1080; DOI: 10.2215/CJN.09600620
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Disclosures
    • Funding
    • Acknowledgments
    • Footnotes
    • References
  • Info & Metrics
  • View PDF

More in this TOC Section

  • APOL1 Kidney Risk Variants and Acute Kidney Injury in Those with COVID-19
  • Telehealth and Kidney Disease Care
  • Time to Abandon Kidney Biopsy to Diagnose Membranous Nephropathy?
Show more Editorials

Cited By...

  • No citing articles found.
  • Google Scholar

Similar Articles

Related Articles

  • Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis
  • PubMed
  • Google Scholar

Keywords

  • ANCA
  • vasculitis
  • glomerulonephritis
  • outcomes

Articles

  • Current Issue
  • Early Access
  • Subject Collections
  • Article Archive
  • ASN Meeting Abstracts

Information for Authors

  • Submit a Manuscript
  • Trainee of the Year
  • Author Resources
  • ASN Journal Policies
  • Reuse/Reprint Policy

About

  • CJASN
  • ASN
  • ASN Journals
  • ASN Kidney News

Journal Information

  • About CJASN
  • CJASN Email Alerts
  • CJASN Key Impact Information
  • CJASN Podcasts
  • CJASN RSS Feeds
  • Editorial Board

More Information

  • Advertise
  • ASN Podcasts
  • ASN Publications
  • Become an ASN Member
  • Feedback
  • Follow on Twitter
  • Password/Email Address Changes
  • Subscribe to ASN Journals

© 2022 American Society of Nephrology

Print ISSN - 1555-9041 Online ISSN - 1555-905X

Powered by HighWire